Lovenox

Lovenox is a brand name of enoxaparin, approved by the FDA in the following formulation(s):

LOVENOX (enoxaparin sodium - injectable; intravenous, subcutaneous)

• 
  Manufacturer: SANOFI AVENTIS US
  
  Approval date: January 23, 2003
  
  Strength(s): 300MG/3ML (100MG/ML) ^[AB]

Has a generic version of Lovenox been approved?

A generic version of Lovenox has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Lovenox and have been approved by the FDA:

enoxaparin sodium injectable; intravenous, subcutaneous

• 
  Manufacturer: SANDOZ INC
  
  Approval date: November 28, 2011
  
  Strength(s): 300MG/3ML (100MG/ML) ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lovenox. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Mixtures of particular LMW heparinic polysaccharides for the prophylaxis/treatment of acute thrombotic events
  Patent 5,389,618
  Issued: February 14, 1995
  Inventor(s): Debrie; Roger
  Assignee(s): Rhone-Poulenc Rorer S.A.
  Heterogeneous intimate admixtures of sulfated heparinic polysaccharides, well suited for the prophylaxis/treatment of acute thrombotic episodes in a human patient, comprise immixture of sulfated polysaccharides having a weight average molecular weight less than that of heparin and which include from 9% to 20% of polysaccharide chains having a molecular weight less than 2,000 daltons and from 5% to 20% of polysaccharide chains having a molecular weight greater than 8,000 daltons, the ratio between the weight average molecular weight and the number average molecular weight thereof ranging from 1.3 to 1.6.
  
  Patent expiration dates:
  
  
  • February 14, 2012
    
    ✓ 
    Patent use: METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Mixtures of particular LMW heparinic polysaccharides for the prophylaxis/treatment of acute thrombotic events
  Patent RE38743
  Issued: June 14, 2005
  Inventor(s): Debrie; Roger
  Assignee(s): Aventis Pharma S.A.
  Heterogeneous intimate admixtures of sulfated heparinic polysaccharides, well suited for the prophylaxis/treatment of acute thrombotic episodes in a human patient, comprise immixture of sulfated polysaccharides having a weight average molecular weight less than that of heparin and which include from 9% to 20% of polysaccharide chains having a molecular weight less than 2,000 daltons and from 5% to 20% of polysaccharide chains having a molecular weight greater than 8,000 daltons, the ratio between the weight average molecular weight and the number average molecular weight thereof ranging from 1.3 to 1.6.
  
  Patent expiration dates:
  
  
  • February 14, 2012
    
    ✓ 
    Patent use: METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

See also...

• Lovenox Consumer Information (Drugs.com)
• Lovenox Consumer Information (Wolters Kluwer)
• Lovenox Consumer Information (Cerner Multum)
• Lovenox Advanced Consumer Information (Micromedex)
• Lovenox AHFS DI Monographs (ASHP)
• Enoxaparin Consumer Information (Wolters Kluwer)
• Enoxaparin Consumer Information (Cerner Multum)
• Enoxaparin Subcutaneous, Injection Advanced Consumer Information (Micromedex)
• Enoxaparin Sodium AHFS DI Monographs (ASHP)